🇺🇸 FDA
Pipeline program

CX-072

CTMX-M-072-001

Phase 2 small_molecule terminated

Quick answer

CX-072 for Solid Tumor is a Phase 2 program (small_molecule) at CytomX Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
CytomX Therapeutics
Indication
Solid Tumor
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials